Sandra A. Mazzoni

Sandra A. Mazzoni

Hematology

10201 Carnegie Avenue
Cleveland, OH 44106

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Response kinetics and depth of response after idecabtagene vicleucel in relapsed/refractory multiple myeloma.

Response kinetics and depth of response after idecabtagene vicleucel in relapsed/refractory multiple myeloma.

Journal: Blood cancer journal

Published: April 03, 2026

BIO26-048: A Meta-Analytic Evaluation of Efficacy and Safety Between Ide-cel and Cilta-cel in Relapsed/Refractory Multiple Myeloma Based on Clinical Trial and Real-World Data.

BIO26-048: A Meta-Analytic Evaluation of Efficacy and Safety Between Ide-cel and Cilta-cel in Relapsed/Refractory Multiple Myeloma Based on Clinical Trial and Real-World Data.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 31, 2026

Isolation and profiling of single circulating tumor cells in myeloma: a new workflow for liquid biopsies.

Isolation and profiling of single circulating tumor cells in myeloma: a new workflow for liquid biopsies.

Journal: BioTechniques

Published: March 24, 2026

Smoldering Multiple Myeloma: Early Intervention or Structured Surveillance? A Comprehensive Review of Evidence for and Against Early Therapy.

Smoldering Multiple Myeloma: Early Intervention or Structured Surveillance? A Comprehensive Review of Evidence for and Against Early Therapy.

Journal: Cancers

Published: March 18, 2026

Multiple Myeloma Screening Education: A Community-Based Health Literacy Intervention.

Multiple Myeloma Screening Education: A Community-Based Health Literacy Intervention.

Journal: Cancer research communications

Published: January 20, 2026

Efficacy and safety of talquetamab in relapsed/refractory multiple myeloma and renal impairment: a quaternary cancer center cohort.

Efficacy and safety of talquetamab in relapsed/refractory multiple myeloma and renal impairment: a quaternary cancer center cohort.

Journal: Blood cancer journal

Published: November 03, 2025

Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists.

Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists.

Journal: Blood reviews

Published: July 25, 2025

Molecular Expression Differences in Specific Blood Mononuclear Cell-Types Identify Patients With AL Amyloidosis.

Molecular Expression Differences in Specific Blood Mononuclear Cell-Types Identify Patients With AL Amyloidosis.

Journal: Journal of cellular and molecular medicine

Published: July 21, 2025

Current management of non-amyloidosis monoclonal gammopathy of renal significance: Clinical features, treatment selections, responses and renal outcomes.

Current management of non-amyloidosis monoclonal gammopathy of renal significance: Clinical features, treatment selections, responses and renal outcomes.

Journal: British journal of haematology

Published: July 18, 2025

Real-World Practice in the Management of Transplant-Eligible Newly Diagnosed Multiple Myeloma: A US-Based Cross-Sectional National Survey.

Real-World Practice in the Management of Transplant-Eligible Newly Diagnosed Multiple Myeloma: A US-Based Cross-Sectional National Survey.

Journal: Clinical lymphoma, myeloma & leukemia

Published: February 24, 2025

Development of an Endothelial Activation and Stress Index (EASIX)-based predictive model for cytokine release syndrome and neurotoxicity after B-cell maturation antigen directed chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma.

Development of an Endothelial Activation and Stress Index (EASIX)-based predictive model for cytokine release syndrome and neurotoxicity after B-cell maturation antigen directed chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma.

Journal: Bone marrow transplantation

Published: February 20, 2025

Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: 14-Year Experience of an Academic Center.

Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: 14-Year Experience of an Academic Center.

Journal: Hematological oncology

Published: December 11, 2024

Showing 1-12 of 30

Last Updated: 09/26/2026